Eygenidion Infirmaryia Trias

	Contact
	Téléphone : Mail : Adresse : PATHOLOGY PAPADIAMANTOPOULOU 20 Athens Grèce Web :

	Consultez cette fiche en intégralité ?
	Consultez cette fiche et près de 50 000 autres fiches de Centres de Recherche dans plus de 30 pays européens sur Expernova.com ! Inscrivez-vous ou contactez-nous pour une démonstration personnalisée. Il s’agit de votre centre de Recherche ? Inscrivez-vous gratuitement et complétez vos informations.

	Profil scientifique partiel

	Quelques documents de Eygenidion Infirmaryia Trias
	Multiparametric detection of bio-molecule conjugated nanoparticles for the diagnostic investigation of mycobacterial infections of humans and animals NANOMYC 2007 - 2010 Sujets : Life Sciences, Biotechnology, Medicine, Health Type de contrat : Specific Targeted Research Project Participants : AGRICULTURAL UNIVERSITY OF ATHENS HELLAS AGRICULTURAL UNIVERSITY OF ATHENS SCHOOL OF ANIMAL SCIENCE/ AGRICULTURAL UNIVERSITY OF ATHENS/DEP. OF ANATOMY PHYSIOLOGY Iera Odos 75, Botanikos HELLAS MALAMIS & MALAMIS CO HELLAS MALAMIS & MALAMIS CO Other LEGAL SKOUFA 52 HELLAS MEDIZONE GERMANY GMBH DEUTSCHLAND MEDIZONE GERMANY GMBH Industry R&T Lessing str. 12 DEUTSCHLAND BIOSURE RT CELL&CO HELLAS BIOSURE RT CELL&CO Industry R&T AGLAYROY 6, KOYKAKI HELLAS UNIVERSITY OF CRETE HELLAS UNIVERSITY OF CRETE DEPARTMENT OF CHEMISTRY, LABORATORY OF ANALYTICAL CHEMISTRY Knossou Avenue-Ampelokipi-University Campus HELLAS EYGENIDION INFIRMARY AGIA TRIAS SA HELLAS EYGENIDION INFIRMARY AGIA TRIAS SA Other PATHOLOGY PAPADIAMANTOPOULOU 20 HELLAS ICOSAGEN AS EESTI ICOSAGEN AS Industry MOLECULAR DIAGNOSTICS 9 NOORUSE STREET EESTI UNIVERSITA DEGLI STUDI DI SASSARI ITALIA UNIVERSITA DEGLI STUDI DI SASSARI DIPARTIMENTO DI SCIENZE BIOMEDICHE, SEZIONE DI MICROBIOLOGIA CLINICA E SPERIMENTALE Viale San Pietro 43B ITALIA VINCA INSTITUTE OF NUCLEAR SCIENCES SERBIA AND MONTENEGRO VINCA INSTITUTE OF NUCLEAR SCIENCES LABORATORY FOR RADIATION PHYSICS AND CHEMISTRY PO Box 522 MIKE PETROVICA ALASA 12-14 SERBIA AND MONTENEGRO ICOSAGEN Estonia ICOSAGEN Industry ICOSAGEN 9 NOORUSE STREET Estonia BIOSURE RT CELL&CO Greece BIOSURE RT CELL&CO Industry R&T AGLAYROY 6, KOYKAKI Greece MEDIZONE GERMANY Germany MEDIZONE GERMANY Industry R&T Lessing str. 12 Germany BIOTECGEN Italy BIOTECGEN Industry BIOTECGEN Viale Rossini, 3 Italy Hide objective WHO reports that tuberculosis results to millions of deaths or disabilities each year, especially in poorer areas of the planet. The problem is exacerbated by the AIDS epidemic that increases disease incidence in developed countries too. However in addition to tuberculosis, exposure to mycobacteria has also been linked to the pathogenesis of sarcoidosis and Crohn's disease that affect millions of people in Europe only. Diagnostic investigation of mycobacterial infections is hampered by the difficulty to detect in a specific manner low populations of mycobacteria or the immunology markers associated with the infections they cause. The NANOMYC project aims to develop a highly sensitive and specific, quantifiable detection system for molecular and immunology diagnostic markers associated with infection caused by M. tuberculosis complex (human and animal tuberculosis, implicated in sarcoidosis) and M. paratuberculosis (animal paratuberculosis, implicated in Crohn's disease). To this goal the consortium will combine nanotechnology and molecular biology incorporating the recent advances on the sequencing of mycobacterial genomes to routine diagnostics. Experts on mycobacteria genetics and nano-technology will produce a number of biomolecules that will be conjugated to a set of functionalized quantum dots with different oproelectrochemical characteristics. The NANOMYC assay will be developed in order to be applied for: a) in-field diagnostics using portable devices for evaluation of liquid samples, and b) manual and automated evaluation of solid samples using fluorescence resonance energy transfer. The final product will be a world innovation and it will target a market of several billion euro/year. Marketing of the NANOMYC assay will be used to sustain the project's administrative and financial platform and continue research activities in order to further the proposed technology for in-vivo diagnostic and therapeutic applications. Source : cordis